NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals announced that its board has approved a stock buyback program on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 2.9% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its stock is undervalued.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings data on Thursday, February, 6th. The biopharmaceutical company reported $7.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. The company's revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.84 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

20 brokers have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $320.00 to $453.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $396.11 in the next twelve months. This suggests that the stock has a possible downside of 1.7%. View Analyst Price Targets for Regeneron Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

Headlines about REGN stock have trended very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,620,000 shares, an increase of 5.6% from the January 15th total of 2,480,000 shares. Based on an average trading volume of 779,400 shares, the short-interest ratio is currently 3.4 days. Currently, 3.2% of the company's shares are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), Celgene (CELG), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Alphabet (GOOG) and Broadcom (AVGO).

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital World Investors (7.57%), Loomis Sayles & Co. L P (3.36%), State Street Corp (3.26%), FMR LLC (2.94%), Alliancebernstein L.P. (1.77%) and Polen Capital Management LLC (1.53%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Janus Henderson Group PLC, Alliancebernstein L.P., Renaissance Technologies LLC, Rockefeller Capital Management L.P., Sustainable Growth Advisers LP, Pictet Asset Management Ltd. and Russell Investments Group Ltd.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, LSV Asset Management, Capital World Investors, Krensavage Asset Management LLC, Skandinaviska Enskilda Banken AB publ , Loomis Sayles & Co. L P, Amundi Pioneer Asset Management Inc. and Sofinnova Investments Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $403.15.

Regeneron Pharmaceuticals has a market capitalization of $44.35 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]